Indicators of pathologic stage of prostate cancer and their use in clinical practice

Urologic Clinics of North America

Volumn 28, Issue 3, 2001, Pages 443-458

  Feneley, Mark R ^b   Partin, Alan W ^b  

^a JOHNS HOPKINS HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DNA; PROSTATE SPECIFIC ANTIGEN;

CANCER GRADING; CANCER STAGING; CANCER SURGERY; CLINICAL PRACTICE; DIAGNOSTIC IMAGING; HUMAN; MALE; MALE GENITAL TRACT CANCER; NEEDLE BIOPSY; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE SURGERY; PROSTATECTOMY; REVIEW; TUMOR LOCALIZATION;

EID: 0034815537     PISSN: 00940143     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0094-0143(05)70154-3     Document Type: Article

References (165)

1. Analysis of risk factors associated with prostate cancer extension to the surgical margin and pelvic node metastasis at radical prostatectomy
2. Percentage of free serum prostate-specific, antigen as a predictor of pathologic features of prostate cancer in a screening population
3. A comparative analysis of sextant and an extended 11-core multisite directed biopsy strategy
4. Comparison of DNA content in primary and lymph node metastases in prostate adenocarcinoma
5. An algorithm for predicting nonorgan confined prostate cancer using the results obtained from sextant core biopsies with prostate specific antigen level
6. The free-to-total serum prostate specific antigen ratio for staging prostate carcinoma
7. Assessment of the vascularization in prostatic carcinoma: A morphometric investigation
8. Relationship between perineural tumor invasion on needle biopsy and radical prostatectomy capsular penetration in clinical stage B adenocarcinoma of the prostate
9. Three-dimensional computer-simulated prostate models. Lateral prostate biopsies increase the detection rate of prostate cancer
10. Value of systematic transition zone biopsies in the early detection of prostate cancer
11. Pelvic lymphadenectomy can be omitted in selected patients with carcinoma of the prostate: Development of a system of patient selection
12. Combining prostate specific antigen with cancer and gland volume to predict more reliably pathological stage: The influence of prostate specific antigen cancer density
13. Extensive repeat transrectal ultrasound guided prostate biopsy in patients with previous benign sextant biopsies
14. Systematic sextant biopsies in the prediction of extracapsular extension at radical prostatectomy
15. Gleason grading of prostatic needle biopsies: Correlation with grade in 316 matched prostatectomies
16. Staging of early prostate cancer: A proposed tumor volume-based prognostic index
17. Prediction of capsular perforation and seminal vesicle invasion in prostate cancer
18. Optimized microvessel density analysis improves prediction of cancer stage from prostate needle biopsies
19. Predictors of pathologic stage in prostatic carcinoma: The role of neovascularity
20. Can ploidy of prostate carcinoma diagnosed on needle biopsy predict radical prostatectomy stage and grade?
21. Carcinoma of the prostate: Prognostic evaluation of certain pathologic features in 208 radical prostatectomies. Examined by the step-section technique
22. Deoxyribonucleic acid ploidy analysis as a predictor of recurrence following radical prostatectomy for stage T2 disease
23. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening
24. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening
25. Prospective evaluation of lateral biopsies of the peripheral zone for prostate cancer detection
26. Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allelotyping
27. Assessment of screening for prostate cancer using the digital rectal examination
28. Systematic sextant biopsies improve preoperative prediction of pelvic lymph node metastases in patients with clinically localized prostatic carcinoma
29. Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen
30. The volume of prostate cancer in the biopsy specimen cannot reliably predict the quantity of cancer in the radical prostatectomy specimen on an individual basis
31. Calculated prostate cancer volume: The optimal predictor of actual cancer volume and pathologic stage
32. Computer simulation of the probability of detecting low volume carcinoma of the prostate with six random systematic core biopsies
33. Predictive value of contralateral biopsies in unilaterally palpable prostate cancer
34. Predictive accuracy of transrectal ultrasound-guided prostate biopsy: Correlations to matched prostatectomy specimens
35. Prognostic significance of seminal vesicle invasion on the radical prostatectomy specimen: Rationale for seminal vesicle biopsies
36. Perineural invasion on prostate needle biopsy: An independent predictor of final pathologic stage
37. Computerized image analysis of nuclear shape as a prognostic factor for prostatic cancer
38. Core cancer length in ultrasound-guided systematic sextant biopsies: A preoperative evaluation of prostate cancer volume
39. Predictive value of the anatomical location of ultrasound-guided systematic sextant prostate biopsies for the nodal status of patients with localized prostate cancer
40. Prediction of extraprostatic extension of prostate cancer based on needle biopsy findings: Perineural invasion lacks significance on multivariate analysis
41. Improved predictability of extracapsular extension and seminal vesicle involvement based on clinical and biopsy findings in prostate cancer in Japanese men
42. Free-to-total prostate specific antigen ratio as a single test for detection of significant stage T1c prostate cancer
43. Impalpable invisible stage T1c prostate cancer: Characteristics and clinical relevance in 100 radical prostatectomy specimens - A different view
44. Diagnostic criteria of limited adenocarcinoma of the prostate on needle biopsy
45. Prostate cancer sampled on sextant needle biopsy: Significance of cancer on multiple cores from different areas of the prostate
46. Prediction of progression following radical prostatectomy: A multivariate analysis of 721 men with long-term follow-up
47. Correlation of prostate cancer nuclear deoxyribonucleic acid, size, shape and Gleason grade with pathological stage at radical prostatectomy
48. The significance of lowgrade prostate cancer on needle biopsy: A radical prostatectomy study of tumor grade, volume, and stage of the biopsied and multifocal tumor
49. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer
50. Use of repeat sextant and transition zone biopsies for assessing extent of prostate cancer
51. Systematic 5 region prostate biopsy is superior to sextant method for diagnosing carcinoma of the prostate
52. Indications for transition zone biopsy in the detection of prostatic carcinoma
53. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer
54. Diagnostic and prognostic markers for human prostate cancer
55. Results of radical prostatectomy in men with locally advanced prostate cancer: Multi-institutional pooled analysis
56. An assessment of the usefulness of serum prostate-specific antigen level and cancer volume in biopsy specimens to predict the extent of prostate cancer
57. Use of systematic biopsy results to predict pathologic stage in patients with clinically localized prostate cancer: A preliminary report
58. Combined nested RT-PCR assay for prostate-specific antigen and prostate-specific membrane antigen in prostate cancer patients: Correlation with pathological stage
59. A comparison of the morphological features of cancer arising in the transition zone and in the peripheral zone of the prostate
60. Indications for preoperative seminal vesicle biopsies in staging of clinically localized prostatic cancer
61. The accuracy of the rectal examination in the diagnosis of prostate carcinoma
62. Systematic sextant biopsies in 651 patients referred for prostate evaluation
63. Comparison of pathologic and clinical evaluation of lymph nodes in prostate cancer: Implications of RTOG data for patient management and trial design and stratification
64. Serum percent-free PSA does not predict extraprostatic spread of prostate cancer
65. Ultrasound guided transrectal core biopsies of the palpably abnormal prostate
66. Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate
67. Excision of the neurovascular bundle at radical prostatectomy in cases with perineural invasion on needle biopsy
68. In vivo and in vitro complex formation of prostate specific antigen with alpha-1-anti-chymotrypsin
69. Preoperative prediction of tumor heterogeneity and recurrence after radical prostatectomy for localized prostatic carcinoma with digital rectal, examination prostate specific antigen and the results of 6 systematic biopsies
70. Incidence of prostate cancer diagnosis in the eras before and after serum prostate-specific antigen testing
71. The palpable nodule of prostatic cancer: Results 15 years after radical excision
72. Computer-assisted comparative analysis of four-sector and six-sector biopsies of the prostate
73. Outcome of sextant biopsy according to gland volume
74. Molecular staging of prostate cancer with the use of an enhanced reverse transcriptase-PCR assay
75. Prostate cancer microvessels: A novel method for three-dimensional reconstruction and analysis
76. Screening for carcinoma of the prostate: A GP based study
77. Ability of preoperative serum prostate-specific antigen value to predict pathologic stage and DNA ploidy: Influence of clinical stage and tumor grade
78. The prostate: MR imaging and spectroscopy. Present and future
79. Differential nuclear matrix protein expression in prostate cancers: Correlation with pathologic stage
80. The value of serum prostate specific antigen determinations before and after radical prostatectomy
81. Which patients with newly diagnosed prostate cancer need a computed tomography scan of the abdomen and pelvis? An analysis based on 588 patients
82. Extended experience with radical prostatectomy for clinical stage T3 prostate cancer: Outcome and contemporary morbidity
83. Free, complexed, and total serum prostate-specific antigen concentrations and their proportions in predicting stage, grade, and deoxyribonucleic acid ploidy in patients with adenocarcinoma of the prostate
84. Two consecutive sets of transrectal ultrasound guided sextant biopsies of the prostate for the detection of prostate cancer
85. Vascular density is a predictor of cancer-specific survival in prostatic carcinoma
86. Immunoscintigraphy with indium-111-capromab pendetide: Evaluation before definitive therapy in patients with prostate cancer
87. Molecular forms of prostate-specific antigen and the human kallikrein gene family: A new era
88. Cancer volume and site of origin of adenocarcinoma of the prostate: Relationship to local and distant spread
89. Nuclear shape analysis for the assessment of local invasion and metastases in clinically localized prostate carcinoma
90. Transrectal ultrasound-guided biopsy causes hematogenous dissemination of prostate cells as determined by RT-PCR
91. The incidence and significance of seminal vesicle invasion in patients with adenocarcinoma of the prostate
92. The role of transrectal ultrasound-guided biopsy-based staging, preoperative serum prostate-specific antigen, and biopsy Gleason score in prediction of final pathologic diagnosis in prostate cancer
93. Clinical and pathologic tumor characteristics of prostate cancer as a function of the number of biopsy cores: A retrospective study
94. The value of the ratio of free-to-total prostate specific antigen for staging purposes in previously untreated prostate cancer
95. The sextant protocol for ultrasound-guided core biopsies of the prostate underestimates the presence of cancer
96. Comparison of digital rectal examination and biopsy results with the radical prostatectomy specimen
97. Update on the appropriate staging evaluation for newly diagnosed prostate cancer
98. The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer
99. Observations on pathology trends in 62,537 prostate biopsies obtained from urology private practices in the United States
100. The use of percent free prostate specific antigen for staging clinically localized prostate cancer
101. The role of free/total prostate-specific antigen ratio in the prediction of final pathologic stage for men with clinically localized prostate cancer
102. Prostate specific antigen in the staging of localized prostate cancer: Influence of tumor differentiation, tumor volume and benign hyperplesia
103. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer: A multi-institutional update
104. The clinical usefulness of prostate specific antigen: Update 1994
105. Use of nuclear morphometry, Gleason histologic scoring, clinical stage, and age to predict disease-free survival among patients with prostate cancer
106. A comparison of nuclear morphometry and Gleason grade as a predictor of prognosis in stage A2 prostate cancer: A critical analysis
107. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer
108. Sextant prostate biopsies: A histopathologic correlation with radical prostatectomy specimens
109. Lower incidence of unsuspected lymph node metastases in 521 consecutive patients with clinically localized prostate cancer
110. 111indiumcapromab pendetide immunoscintigraphy in the prediction of lymph node involvement in high risk prostate carcinoma patients
111. Prostate specific antigen: A decade of discovery - What we have learned and where we are going
112. Genetically engineered neural networks for predicting prostate cancer progression after radical prostatectomy
113. Natural history of progression after PSA elevation following radical prostatectomy
114. Prostate-specific antigen after anatomic radical retropubic prostatectomy: Patterns of recurrence and cancer control
115. The optimal systematic prostate biopsy scheme should include 8 rather than 6 biopsies: Results of a prospective clinical trial
116. Clinical and pathological characteristics, and recurrence rates of stage T1c versus T2a or T2b prostate cancer
117. Systematic biopsies accurately predict extracapsular extension of prostate cancer and persistent/recurrent detectable PSA after radical prostatectomy
118. A single positive prostate biopsy in six does not predict a low-volume prostate tumour
119. Is ultrasound guidance necessary for transrectal prostate biopsy?
120. Comparison of magnetic resonance imaging and ultrasonography in staging early prostate cancer: Results of a multi-institutional cooperative trial
121. Predicting the risk of lymph node involvement using the pretreatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer
122. Diagnostic yield of repeated transrectal ultrasound-guided biopsies stratified by specific histopathologic diagnoses and prostate specific antigen levels
123. Microvessel density in core biopsies of prostatic adenocarcinoma: A stage predictor?
124. BCL-2 and p53 expression in clinically localized prostate cancer predicts response to external beam radiotherapy
125. The TNM classification of prostate cancer
126. The European Randomized Study of Screening for Prostate Cancer (ERSPC): An update
127. The percent of cores positive for cancer in prostate needle biopsy specimens is strongly predictive of tumor stage and volume at radical prostatectomy
128. Staging laparoscopic pelvic lymphadenectomy in prostate cancer
129. Topography of neovascularity in human prostate carcinoma
130. Tumor angiogenesis correlates with progression after radical prostatectomy but not with pathologic stage in Gleason sum 5 to 7 adenocarcinoma of the prostate
131. Has there been a recent shift in the pathological features and prognosis of patients treated with radical prostatectomy?
132. Quantitative polymerase chain reaction does not improve preoperative prostate cancer staging: A clinicopathological molecular analysis of 121 patients
133. Prediction of post-radical prostatectomy pathological outcome for stage T1c prostate cancer with percent free prostate specific antigen: A prospective multicenter clinical trial
134. Prostate specific antigen level and Gleason score in predicting the stage of newly diagnosed prostate cancer
135. p53 and bcl-2 immunohistochemistry in pretreatment prostate needle biopsies to predict recurrence of prostate cancer after radical prostatectomy
136. Making the most out of six systematic sextant biopsies
137. Large, organ confined, impalpable transition zone prostate cancer: Association with metastatic levels of prostate specific antigen
138. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients
139. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate
140. Correlation of prostate needle biopsy and radical prostatectomy Gleason grade in academic and community settings
141. Perineural invasion and seminal vesicle involvement predict pelvic lymph node metastasis in men with localized carcinoma of the prostate
142. Does site specific labeling of sextant biopsy cores predict the site of extracapsular extension in radical prostatectomy surgical specimen
143. Prognostic indicators in patients with seminal vesicle involvement following radical prostatectomy for clinically localized prostate cancer
144. Staging of prostate cancer: Results of Radiology Diagnostic Oncology Group project comparison of three MR imaging techniques
145. Prediction of prostate cancer volume using prostate-specific antigen levels, transrectal ultrasound, and systematic sextant biopsies
146. Efficacy of transrectal ultrasound-guided seminal vesicle biopsies in the detection of seminal vesicle invasion by prostate cancer
147. Routine transition zone and seminal vesicle biopsies in all patients undergoing transrectal ultrasound guided prostate biopsies are not indicated
148. Effect of the number of core biopsies of the prostate on predicting Gleason score of prostate cancer
149. Minimal carcinoma in prostate needle biopsy specimens: Diagnostic features and radical prostatectomy follow-up
150. Number of positive systematic sextant biopsies predicts surgical margin status at radical prostatectomy
151. The influence of prostate size on cancer detection
152. Interobserver variation in assessment of the prostate by digital rectal examination
153. Ability to predict biochemical progression using Gleason score and a computer-generated quantitative nuclear grade derived from cancer cell nuclei
154. Quantitative nuclear morphometry, Markovian texture descriptors, and DNA content captured on a CAS-200 Image analysis system, combined with PCNA and HER-2/neu immunohistochemistry for prediction of prostate cancer progression
155. Quantification of angiogenesis in solid human tumours: An international consensus on the methodology and criteria of evaluation
156. Histological grade, perineural infiltration, tumour-infiltrating lymphocytes and apoptosis as determinants of longterm prognosis in prostatic adenocarcinoma
157. Invasion of Denonvilliers' fascia in radical prostatectomy specimens
158. One core positive prostate biopsy is a poor predictor of cancer volume in the radical prostatectomy specimen
159. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma
160. Ability of sextant biopsies to predict radical prostatectomy stage
161. Significance of small foci of Gleason score 7 or greater prostate cancer on needle biopsy
162. Low p27 expression predicts poor disease-free survival in patients with prostate cancer
163. Comparison of nuclear morphometric results between needle biopsy and surgical specimens from patients with prostate cancer